Secondary analysis of the SELECTION trial in moderately to severely active ulcerative colitis: filgotinib 200 mg gave more endo-histological remission than placebo (week 10: 6.7% vs 1.8%; week 58: 12.1% vs 5.1%), with post hoc gene changes suggesting mucosal repair.
Secondary analysis
Magro et al. Association between endo-histological outcomes and colonic mucosal transcriptomic profiles in patients with ulcerative colitis receiving filgotinib